The company’s antibody therapy has been determined to be ineffective against the omicron variant that now dominates Covid-19 cases worldwide.
Regeneron Expects Zero Covid Antibody Sales For The First Quarter Of 2022
The company’s antibody therapy has been determined to be ineffective against the omicron variant that now dominates Covid-19 cases worldwide.